Irinotecan in combined-modality therapy for locally advanced non-small-cell lung cancer

Hak Choy, Rob Macrae

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The management of non-small-cell lung cancer is undergoing rapid evolution. Although the advent of combined-modality therapy has led to improved survival, most patients eventually succumb to the disease. The arrival of a new generation of chemotherapeutic agents - including the taxanes, gemcitabine (Gemzar), and topoisomerase inhibitors such as irinotecan (Camptosar, CPT-11) - offers the hope of advances against this malignancy. Irinotecan, a camptothecin derivative, has shown impressive activity in a variety of solid tumors, including non-small-cell lung cancer. It is believed to act by stabilizing the topoisomerase-DNA complex formed during diverse cellular processes, including replication and transcription. A considerable body of evidence also demonstrates that camptothecin and its derivatives possess substantial radiosensitization properties. This article will review the in vitro and in vivo data on irinotecan's ability to render tumors more susceptible to ionizing radiation. It will then focus on experience with irinotecan and thoracic radiation in the treatment of non-small-cell lung cancer, which has yielded acceptable toxicity results and response rates in excess of 60% in early trials. It is hoped that newer treatment strategies - such as the combination of radiation and irinotecan in lung cancer - will significantly impact cure rates in the future.

Original languageEnglish (US)
Pages (from-to)31-36
Number of pages6
JournalOncology
Volume15
Issue number1 SUPPL. 1
StatePublished - 2001

Fingerprint

irinotecan
Combined Modality Therapy
Non-Small Cell Lung Carcinoma
gemcitabine
Camptothecin
Topoisomerase Inhibitors
Radiation
Taxoids
Neoplasms
Type I DNA Topoisomerase
Ionizing Radiation

ASJC Scopus subject areas

  • Oncology

Cite this

Irinotecan in combined-modality therapy for locally advanced non-small-cell lung cancer. / Choy, Hak; Macrae, Rob.

In: Oncology, Vol. 15, No. 1 SUPPL. 1, 2001, p. 31-36.

Research output: Contribution to journalArticle

@article{a46936b2df3c41d8899606a99f771f93,
title = "Irinotecan in combined-modality therapy for locally advanced non-small-cell lung cancer",
abstract = "The management of non-small-cell lung cancer is undergoing rapid evolution. Although the advent of combined-modality therapy has led to improved survival, most patients eventually succumb to the disease. The arrival of a new generation of chemotherapeutic agents - including the taxanes, gemcitabine (Gemzar), and topoisomerase inhibitors such as irinotecan (Camptosar, CPT-11) - offers the hope of advances against this malignancy. Irinotecan, a camptothecin derivative, has shown impressive activity in a variety of solid tumors, including non-small-cell lung cancer. It is believed to act by stabilizing the topoisomerase-DNA complex formed during diverse cellular processes, including replication and transcription. A considerable body of evidence also demonstrates that camptothecin and its derivatives possess substantial radiosensitization properties. This article will review the in vitro and in vivo data on irinotecan's ability to render tumors more susceptible to ionizing radiation. It will then focus on experience with irinotecan and thoracic radiation in the treatment of non-small-cell lung cancer, which has yielded acceptable toxicity results and response rates in excess of 60{\%} in early trials. It is hoped that newer treatment strategies - such as the combination of radiation and irinotecan in lung cancer - will significantly impact cure rates in the future.",
author = "Hak Choy and Rob Macrae",
year = "2001",
language = "English (US)",
volume = "15",
pages = "31--36",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "1 SUPPL. 1",

}

TY - JOUR

T1 - Irinotecan in combined-modality therapy for locally advanced non-small-cell lung cancer

AU - Choy, Hak

AU - Macrae, Rob

PY - 2001

Y1 - 2001

N2 - The management of non-small-cell lung cancer is undergoing rapid evolution. Although the advent of combined-modality therapy has led to improved survival, most patients eventually succumb to the disease. The arrival of a new generation of chemotherapeutic agents - including the taxanes, gemcitabine (Gemzar), and topoisomerase inhibitors such as irinotecan (Camptosar, CPT-11) - offers the hope of advances against this malignancy. Irinotecan, a camptothecin derivative, has shown impressive activity in a variety of solid tumors, including non-small-cell lung cancer. It is believed to act by stabilizing the topoisomerase-DNA complex formed during diverse cellular processes, including replication and transcription. A considerable body of evidence also demonstrates that camptothecin and its derivatives possess substantial radiosensitization properties. This article will review the in vitro and in vivo data on irinotecan's ability to render tumors more susceptible to ionizing radiation. It will then focus on experience with irinotecan and thoracic radiation in the treatment of non-small-cell lung cancer, which has yielded acceptable toxicity results and response rates in excess of 60% in early trials. It is hoped that newer treatment strategies - such as the combination of radiation and irinotecan in lung cancer - will significantly impact cure rates in the future.

AB - The management of non-small-cell lung cancer is undergoing rapid evolution. Although the advent of combined-modality therapy has led to improved survival, most patients eventually succumb to the disease. The arrival of a new generation of chemotherapeutic agents - including the taxanes, gemcitabine (Gemzar), and topoisomerase inhibitors such as irinotecan (Camptosar, CPT-11) - offers the hope of advances against this malignancy. Irinotecan, a camptothecin derivative, has shown impressive activity in a variety of solid tumors, including non-small-cell lung cancer. It is believed to act by stabilizing the topoisomerase-DNA complex formed during diverse cellular processes, including replication and transcription. A considerable body of evidence also demonstrates that camptothecin and its derivatives possess substantial radiosensitization properties. This article will review the in vitro and in vivo data on irinotecan's ability to render tumors more susceptible to ionizing radiation. It will then focus on experience with irinotecan and thoracic radiation in the treatment of non-small-cell lung cancer, which has yielded acceptable toxicity results and response rates in excess of 60% in early trials. It is hoped that newer treatment strategies - such as the combination of radiation and irinotecan in lung cancer - will significantly impact cure rates in the future.

UR - http://www.scopus.com/inward/record.url?scp=0035222087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035222087&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 31

EP - 36

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 1 SUPPL. 1

ER -